Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) entered into a definitive merger agreement to be acquired by the global healthcare enterprise Servier, under a cash tender offer valued at approximately $2.5 billion. This strategic acquisition was designed to expand Servier's global rare oncology portfolio and integrate Day One's targeted therapies and pipeline assets, which also included the earlier acquisition of Mersana Therapeutics.